Related Experiment Videos
[Current therapeutic possibilities in cutaneous larva migrans]
P Wolf1, F R Ochsendorf, R Milbradt
1Abteilung II, Klinikum der J.W. Goethe Universität Frankfurt/Main.
Summary
Cutaneous larva migrans treatment varies. Topical thiabendazole is effective for skin-only cases, while albendazole or ivermectin are safer systemic options when topical treatments fail.
Area of Science:
- Dermatology
- Infectious Diseases
- Parasitology
Context:
- Cutaneous larva migrans (CLM) treatment recommendations lack uniformity.
- Current therapeutic options present challenges in availability and efficacy.
- Skin-exclusive CLM cases primarily warrant topical therapy.
Purpose:
- To review and compare treatment options for cutaneous larva migrans.
- To highlight effective and safer alternatives for CLM management.
Summary:
- Topical thiabendazole offers efficacy with minimal systemic side effects for localized CLM.
- Systemic therapy is necessary if topical treatments are ineffective.
- Oral albendazole (3 days) and ivermectin (single dose) are preferred systemic treatments due to improved safety profiles over oral thiabendazole.
Impact:
- Provides clinicians with evidence-based guidance for optimal CLM treatment selection.
- Promotes the use of safer and more effective systemic therapies like albendazole and ivermectin.
- Addresses the need for standardized and accessible treatment protocols for cutaneous larva migrans.